Major INC Research investor sells shares for $177m

By Gareth Macdonald contact

- Last updated on GMT

INC Research HQ in North Carolina
INC Research HQ in North Carolina

Related tags: Central nervous system, U.s. securities and exchange commission, Nervous system

INC Research investor Avista Capital Partners has offloaded shares just days after the CRO was upgraded by a number of analysts.

The divestiture – disclosed in a US Securities and Exchange Commission (SEC) filing posted today​ – saw Avista sell just over four million shares for $177.2m (€158.7m) at an average price of $44 per share.

In July, INC raised its guidance reported 14.2% net service revenue growth in Q2 and raised its guidance, citing revenue growth in CNS (central nervous system) and oncology business, new customers and repeat business as drivers for the gains.

At the time CEO Jamie Macdonald said: "On the customer front, we continue to see strong repeat business while winning new awards from new customers with novel molecules exploring innovative approaches for patients. 

Our launch during the quarter of the CRO industry's first Site Advocacy Group has been highly successful with positive customer feedback, holding significant potential to improve the way in which clinical trials are conducted in the future.”

Analyst attention

As a result, INC has attracted the attention of a number of analysts in recent times.

Earlier this month Zacks​ upped its rating from “sell” to “strong-buy” and set the firm a price target of $58 per share. Last week, Credit Suisse​ began covering the CRO.  

Avista​ signalled its intention to sell some of its holding in INC in an SEC filing earlier this month, as did Teachers' Private Capital, the private investment arm of Ontario Teachers' Pension Plan (OTPP) Board.

It is the second time Avista has reduced its holding in INC this year. In May, according to another SEC filing​, the New York-headquartered group sold around six and a half million shares in the CRO for $195m.

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Related suppliers

Follow us

Products

View more

Webinars